HIT Consultant August 21, 2024
What You Should Know:
– PreciseDx, a pioneering company in oncology diagnostics utilizing artificial intelligence (AI) raises $20.7M in Series B funding led by Eventide Asset Management with participation from Labcorp, Quest Diagnostics, GenHenn Capital Venture, and existing investors. This brings the company’s total funding to date to $31.5M.
– The new funding will enable PreciseDx to accelerate its growth and expand its operations. The company plans to invest in talent acquisition, product development, and strategic partnerships. Additionally, PreciseDx will continue to explore new applications for its technology and expand its reach into global markets.
Leveraging AI for Improved Oncology Diagnostics
PreciseDx’s AI-powered platform offers a novel approach to oncology diagnostics, focusing on morphology-driven disease analysis. By analyzing...
Today's Sponsors
Today's Sponsor